Title : Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.

Pub. Date : 2019 Dec

PMID : 31604667






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 An ARID1A-deficient case that was resistant to multiple cytotoxic drugs, including paclitaxel plus carboplatin in the adjuvant and etoposide plus irinotecan in the first-line treatment, exhibited a dramatic response to gemcitabine in the second-line treatment. Carboplatin AT-rich interaction domain 1A Homo sapiens